Appclon "Developing Autoimmune Therapeutics for COVID-19 Treatment"

AM201 Under Development as a Treatment for Severe COVID-19 Patients

[Asia Economy Reporter Minwoo Lee] Abclone, a company specializing in antibody-based therapeutics, is developing an autoimmune disease treatment as a therapy for COVID-19.

Abclone announced on the 7th that it is developing its autoimmune disease treatment AM201 as a therapy for cytokine release syndrome (CRS) experienced by severe COVID-19 patients.

AM201 is a bispecific antibody therapeutic that simultaneously inhibits 'TNF-α' and 'IL-6', disease proteins known to cause autoimmune diseases. It is a new drug candidate discovered through Abclone's bispecific antibody development platform 'AppiMap', and it is explained that the indication can be expanded to various diseases accompanied by CRS caused by excessive cytokine secretion.

An Abclone official stated, "Global big pharma companies' IL-6 inhibitors have repeatedly failed in clinical trials aimed at improving COVID-19 symptoms," adding, "AM201 is expected to have improved efficacy compared to inhibitors that only suppress IL-6, as it simultaneously inhibits TNF-α and IL-6 in a bispecific antibody form."

Meanwhile, data packaging work is also underway to facilitate the technology transfer of AM201. Abclone said, "We are currently in the final cell line selection stage for mass production and are preparing for technology transfer with indications for treating various diseases accompanied by autoimmune diseases including rheumatoid arthritis and CRS."

This content was produced with the assistance of AI translation services.